MDxHealth introduces ConfirmMDx for prostate cancer, a novel test that helps urologists distinguish patients who have a true-negative biopsy from those who may have occult cancer. Over 650,000 American men receive a negative prostate biopsy result each year; however, 25-35% of these results are false-negative. Misdiagnosis is often due to the limitations of current biopsy procedures, which are commonly described as sampling errors. Consequently, the standard of care for men with high-risk factors, but no evidence of cancer in a biopsy, is limited to continued surveillance and repeat biopsies, often on prostate cancer-free men. ConfirmMDx can help alleviate these errors and help patients realize their true diagnosis.